R&D Amortization Under Section 174 — The TCJA Change That Shocked Tech Companies

For most of American tax history, companies could immediately deduct research and experimentation (R&E) expenses under § 174 — spent $10 million on R&D this year, deduct $10 million this year. That changed dramatically starting January 1, 2022. A provision buried in the 2017 Tax Cuts and Jobs Act, originally expected to be reversed before it took effect, required companies to capitalize and amortize all domestic R&E costs over 5 years (and foreign R&E over 15 years) rather than deducting them immediately. For software companies, biotech startups, and any business that treats R&D spending as a major operating expense, this change — which took many companies by surprise when it wasn't reversed — increased effective tax liability by tens or hundreds of millions of dollars and generated negative taxable income for some cash-flow-positive businesses. As of 2026, the 5-year amortization requirement remains in effect, despite persistent bipartisan support for restoration of immediate expensing.

Current Law (2026)

Legal Authority

• 26 U.S.C. § 174(a) (pre-2022 version) — The original provision: taxpayers could elect to deduct in full R&E expenditures paid or incurred in connection with a trade or business in the current year, OR capitalize and amortize over at least 60 months
• 26 U.S.C. § 174 (post-TCJA, effective 2022) — Eliminated the immediate deduction option; made 5-year (domestic) and 15-year (foreign) amortization mandatory, with midpoint convention
• 26 U.S.C. § 174(c) — Exclusions: § 174 does not apply to land acquisition or improvement costs, depreciable property used in research (those go through § 167/168), or costs to identify mineral deposits
• 26 U.S.C. § 174(c)(3) — Software development is explicitly treated as an R&E expenditure
• 26 U.S.C. § 41 — The separate R&D tax credit (up to 20% of qualified research expenses above a base amount) is calculated independently of § 174 amortization
• 26 U.S.C. § 280C(c) — Anti-double-benefit rule: the § 41 research credit generally requires a dollar-for-dollar reduction in the § 174 deduction, unless the taxpayer elects a reduced credit rate (the reduced credit election avoids this)

The Mechanics of 5-Year Amortization

Under the post-2021 rules, every dollar of domestic R&E must be capitalized and amortized over 60 months (5 years) starting at the midpoint of the year the cost was incurred.

Year 1 midpoint convention: Only 6 months of deduction in Year 1, regardless of when you incurred the R&E cost. If you spent $12 million on R&D in 2022, your 2022 deduction was only $1.2 million (10% = 6/60 months). The remaining $10.8 million amortizes over the next 4.5 years.

Full amortization schedule for $12 million spent in 2022:

• 2022 (Year 1, 6 months): $1.2M deduction
• 2023: $2.4M deduction
• 2024: $2.4M deduction
• 2025: $2.4M deduction
• 2026: $2.4M deduction
• 2027 (Year 6, 6 months): $1.2M deduction

Total: $12M deducted over 6 tax years. Compare to the pre-2022 world: $12M deducted in full in 2022.

Cash flow impact: A company spending $10 million on R&D annually faces a permanent "wedge" between actual spending and deductible amortization. In steady-state (after 5 years), the annual deduction equals annual spending — but the transition created a 5-year period of massively understated deductions and overstated taxable income relative to economic reality.

Why This Matters (And Who It Hit Hardest)

The backstory: The TCJA 2017 included § 174 amortization as a revenue-raiser to offset rate cuts, deliberately delayed until 2022, apparently expecting Congress to reverse it before it took effect. Congress did not. When the provision hit in early 2023 (when companies filed their 2022 returns), tech companies, biotech firms, and startups discovered they owed far more tax than expected.

Who was most affected:

• Software companies and startups: Any company where payroll for engineers, developers, or scientists is a major cost center is doing "research or experimental" work under § 174's broad definition. A SaaS company with 50 engineers whose salaries total $8 million per year suddenly couldn't deduct those costs immediately.
• Biotech and pharma: Drug development R&D is quintessentially § 174 activity. Companies with no revenue spending years in clinical trials shifted from immediate deductions to a 5-year amortization schedule — creating positive taxable income on the books before the drug ever earns a dollar.
• Startups with losses: Pre-2022, R&D-intensive startups typically had large deductible losses that accumulated as net operating loss carryforwards, creating future tax deductions. Post-2021, those losses are smaller in Year 1 because R&D costs are spread over 5 years — meaning less NOL accumulation and potentially tax liability in profitable years.

Interaction with the § 41 Research Credit

The § 41 research and development tax credit remains available and is calculated separately. But the § 280C interaction matters:

• Without a reduced credit election: If you claim a $200,000 § 41 credit, you must reduce your § 174 amortizable base by $200,000. In effect, the credit reduces your future amortization deductions dollar-for-dollar.
• With a reduced credit election: You can elect a reduced credit rate (approximately 65% of the full credit for C corporations) and preserve the full § 174 base. Many companies find the reduced credit election produces better overall results when combined with the amortization base.

How It Affects You

If you're a startup or technology company that spent heavily on R&D in 2022–2025: The One Big Beautiful Bill Act (OBBBA, signed 2025) restored immediate § 174 expensing for costs incurred after January 19, 2025 — but costs incurred before that date remain in the 5-year (domestic) or 15-year (foreign) amortization queue. If your company spent $5 million/year on domestic R&D in 2022, 2023, and 2024, you have roughly $12 million of capitalized § 174 assets as of early 2025, generating amortization deductions through 2027-2030. Your tax advisor should have a schedule of these amortizing assets. You cannot accelerate the deduction — the OBBBA restoration is prospective only. Plan your estimated tax payments accordingly; the ongoing amortization tail reduces taxable income over the next few years in ways that can be hard to model without a detailed schedule.

If your company files for the § 41 R&D tax credit: Post-OBBBA, for R&D costs incurred after January 19, 2025, you return to the pre-2022 world: immediate expensing of R&E costs AND the ability to claim the § 41 credit (with the standard § 280C basis reduction or reduced credit election). For costs from the 2022-2025 mandatory capitalization period, the credit and amortization interactions are more complex — the credit reduces the amortizable base dollar-for-dollar (unless you elected reduced credit). Your CPA should verify that your § 41 credit calculations for 2022-2025 properly reflect the amortization interaction, as IRS audit attention in this area is elevated.

If you're in biotech or pharma with foreign R&D: The 15-year amortization requirement for foreign R&E expenditures was also suspended by the OBBBA. For offshore clinical trials, foreign laboratory costs, and manufacturing process R&D conducted abroad, costs incurred after January 19, 2025 are again immediately deductible. The pre-OBBBA 15-year amortization tail on foreign R&D from 2022-2025 is even longer than domestic — a company with $50M in foreign R&D from 2022 is amortizing that at only $3.3M/year through 2037. Track these separately from domestic R&D.

If you're a software company uncertain about which development costs qualify: The explicit § 174(c)(3) coverage of "software development" created significant ambiguity during 2022-2025: does every engineer's salary on a product team need to be capitalized? The IRS's guidance (Rev. Proc. 2023-11) helps, but classification disputes between § 174 (must capitalize) and ordinary § 162 business expenses (immediately deductible) remain live audit issues for that period. With OBBBA restoring immediate expensing, the classification question matters less for 2025+ costs — but if your company has unresolved § 174 classifications for 2022-2025, resolve them before an IRS examination: internal documentation of which costs were treated as § 174 vs. § 162, and the methodology used, is critical.

State Variations

This is a critical state tax issue. Many states conform to federal § 174 treatment, but California specifically decoupled from TCJA § 174. California continues to allow immediate expensing of R&E costs for California franchise/income tax purposes. This means California-based tech companies pay more federal tax on R&D than their California tax — a significant divergence. New York, Texas, and most other states have followed federal law with mandatory amortization. Check your state's conformity date to federal law.

Pending Legislation

Restoring immediate R&D expensing under § 174 has strong bipartisan support. The American Innovation and Jobs Act (introduced in the Senate, sponsored by Senators Crapo and Warner) would retroactively restore immediate deduction for domestic R&E effective 2022 and eliminate the foreign 15-year amortization. As of early 2026, the legislation has not passed, but it remains active in negotiations around broader tax bills. If enacted retroactively, companies would need to file amended returns for 2022 and 2023 to claim the larger deductions, generating significant refunds.

Recent Developments

The IRS issued Rev. Proc. 2023-11 providing guidance on the § 174 amortization change, including how to treat costs incurred in ongoing multi-year research projects. The IRS also clarified which software development costs are captured by the explicit § 174(c)(3) rule versus the general § 174 test. Litigation has not yet produced definitive court decisions on how broadly § 174's definition of "research or experimental" extends — for example, whether market research, customer discovery, or certain engineering services count as § 174 expenditures or are ordinary § 162 business expenses.

• OBBBA restores immediate Section 174 expensing (2025): The One Big Beautiful Bill Act prospectively restored immediate expensing for Section 174 research and experimental expenditures for costs incurred after January 19, 2025. The TCJA's mandatory capitalization requirement — which required 5-year (domestic) or 15-year (foreign) amortization of R&D costs beginning in 2022 — was widely condemned by technology companies, pharmaceutical manufacturers, and startup ecosystems as an inadvertent tax increase. Companies that had capitalized R&D costs in 2022-2025 under the TCJA's mandatory rule still carry amortization tails through 2027-2040; the OBBBA restoration only applies prospectively.
• The 2022-2025 amortization backlog — cash flow and EPS impact: The mandatory § 174 capitalization rule applied for three full tax years (2022, 2023, 2024) and part of 2025 before OBBBA relief. Companies that spent heavily on R&D during this period accumulated large capitalized asset balances that are amortizing at 20% per year (domestic) or 6.67% (foreign). A company that spent $100M on domestic R&D annually during 2022-2024 has approximately $240M in capitalized § 174 assets as of January 1, 2025, generating $48M in annual amortization deductions through 2027. This "shadow depreciation" from pre-OBBBA capitalized costs continues to affect taxable income calculations for several years.
• Software development costs — the § 174(c)(3) question: The TCJA's mandatory § 174 capitalization created an unsolved problem for software companies: § 174(c)(3) explicitly covers "any amount paid or incurred in connection with the development of any software." This brought routine software development (internal tools, product features, website updates) into mandatory 5-year capitalization — affecting tens of thousands of companies with internal software teams. The OBBBA restored immediate expensing for all § 174 costs (including software development) prospectively, but the 2022-2025 period software development costs remain in the amortization queue. IRS has been auditing companies' § 174 cost classifications (what qualifies as "in connection with" software development) for the mandatory capitalization years.
• R&D credit (§ 41) and § 174 interaction: The § 41 R&D tax credit — a permanent credit of 20% of qualified research expenses above a base amount — is separate from the § 174 expensing rules. When § 174 amortization was mandatory, companies still claimed § 41 credits on the same expenditures; the credit basis is reduced by the credit amount, and the remaining amount is capitalized. The OBBBA's restoration of immediate § 174 expensing eliminates the deduction/credit interaction complexity for 2025+ costs, but the 2022-2025 "overlap period" requires careful calculation of §§ 174 and 41 separately for those prior years.